Company: DHR
Filing Date: 2025-10-21
Form Type: 10-Q
Source: 0000313616-25-000182
Chunk: 45

Company: DANAHER CORP /DE/
Filing Date: 2025-10-21
Form: 10-Q
Item: Item 1
Chunk 45
---
 manufacture and delivery of biological medicines.  The Company’s solutions support a broad range of biotherapeutics including monoclonal antibodies, recombinant proteins, replacement therapies such as insulin and vaccines, as well as novel cell, gene, mRNA and other nucleic acid therapies.

Biotechnology Selected Financial Data 

 Three-Month Period EndedNine-Month Period Ended($ in millions)September 26, 2025September 27, 2024September 26, 2025September 27, 2024Sales$1,798 $1,653 $5,260 $4,890 Operating profit352 390 1,324 1,177 Depreciation38 36 110 113 Amortization of intangible assets231 218 672 650 Operating profit as a % of sales19.6 %23.6 %25.2 %24.1 %Depreciation as a % of sales2.1 %2.2 %2.1 %2.3 %Amortization as a % of sales12.8 %13.2 %12.8 %13.3 %

Sales Growth and Core Sales Growth% Change Three-Month Period Ended September 26, 2025 vs. Comparable 2024 Period% Change Nine-Month Period Ended September 26, 2025 vs. Comparable 2024 PeriodTotal sales growth (GAAP)9.0 %7.5 %Impact of:Currency exchange rates (2.5)%(1.0)%Core sales growth (non-GAAP)6.5 %6.5 %

Price increases in the segment contributed 2.5% and 2.0%, respectively, to sales growth on a year-over-year basis during the three and nine-month periods ended September 26, 2025 and are reflected as a component of core sales above.

Total segment sales increased 9.0% and 7.5% during the three and nine-month periods, respectively.  The increase in segment sales in the three and nine-month periods was led by increased core sales and to a lesser extent by the impact of currency exchange rates.  The year-over-year increase in total segment core sales in both periods was led by increased sales of consumables, partially offset by declines in equipment sales.  Geographically, the increase in core sales was led by North America in the three-month period and North America